Practically Speaking: Neoadjuvant Chemo/IO for Resectable NSCLC - surgical

To be added to the distribution list, please email: DDeCastro@southlakeregional.org

In this episode, Dr. Jonathan Spicer will discuss the perioperative management of NSCLC – focusing on how to choose which patients should get perioperative chemo/IO vs. ChemoRads and how to implement into daily practice.

Key Opinion Leader: 
Dr. Jonathan Spicer

Associate Professor of Surgery – McGill University.
Medical Director MUHC Thoracic Oncology Network.

Co-director of the MUHC Thoracic Oncology Clinical trials Unit.

Host:
Dr. Shaqil Kassam 
skassam@southlakeregional.org
Medical Oncologist
Stronach Regional Cancer Centre, Newmarket, Ontario 

Outline:
0:00 - Introductions
3:00 – New standard of care?
6:20 – Checkmate 816 – logistical consideration.
19:10 – Surgical downstaging
24:00 – Implementation into practice (Stage IIIs, EGFR, Follow up).

Previous Episodes:
Gastric Cancer: http://tobtr.com/12051154

NGS: http://tobtr.com/12072620

Paxlovid and Cancer treatment:http://tobtr.com/12090165

Billiary Tract Cancers: http://tobtr.com/12135321

Adjuvant immunotherapy for kidney cancers: http://tobtr.com/12149885
Neoadjuvant chemo/IO for NSCLC: http://tobtr.com/12154678

Should I still get Colonoscopy screening: http://tobtr.com/12169953